Which has preferable earnings and valuation, NERV or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is NERV or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% Invizyne Technologies N/A N/A N/A

Do analysts rate FATE or IZTC?

Fate Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 148.79%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Fate Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, FATE or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Fate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 36.11 -$136.32M -$1.09 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Do analysts prefer FBRX or IZTC?

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 281.55%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Forte Biosciences is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, FBRX or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is FBRX or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Invizyne Technologies N/A N/A N/A

Do analysts rate IZTC or ACIU?

AC Immune has a consensus target price of $7.50, indicating a potential upside of 224.68%. Given AC Immune's stronger consensus rating and higher probable upside, analysts clearly believe AC Immune is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AC Immune 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation & earnings, IZTC or ACIU?

Invizyne Technologies has higher earnings, but lower revenue than AC Immune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A AC Immune $4.31M 54.54 -$85.03M -$0.82 N/A

Do analysts rate CHRS or IZTC?

Coherus Oncology currently has a consensus price target of $8.67, indicating a potential upside of 519.05%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CHRS or IZTC?

Coherus Oncology has higher revenue and earnings than Invizyne Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coherus Oncology $42.17M 5.12 $168.02M $1.67 0.84 Invizyne Technologies N/A N/A N/A N/A N/A

Invizyne Technologies (IZTC) Competitors

$7.10 -0.60 (-7.79%)

As of 06/12/2026

Compare

IZTC vs. NERV, FATE, FBRX, ACIU, and CHRS

Should you buy Invizyne Technologies stock or one of its competitors? MarketBeat compares Invizyne Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invizyne Technologies include Minerva Neurosciences (NERV), Fate Therapeutics (FATE), Forte Biosciences (FBRX), AC Immune (ACIU), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry.

How does Invizyne Technologies compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Minerva Neurosciences had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Invizyne Technologies. Minerva Neurosciences' average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Very Positive
Invizyne Technologies	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 132.82%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Invizyne Technologies	N/A	N/A	N/A

34.6% of Minerva Neurosciences shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Minerva Neurosciences beats Invizyne Technologies on 7 of the 8 factors compared between the two stocks.

How does Invizyne Technologies compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Invizyne Technologies has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Invizyne Technologies' return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Invizyne Technologies	N/A	N/A	N/A

97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fate Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 148.79%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Fate Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies has lower revenue, but higher earnings than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	36.11	-$136.32M	-$1.09	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Fate Therapeutics had 7 more articles in the media than Invizyne Technologies. MarketBeat recorded 7 mentions for Fate Therapeutics and 0 mentions for Invizyne Technologies. Fate Therapeutics' average media sentiment score of 1.08 beat Invizyne Technologies' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Fate Therapeutics	Positive
Invizyne Technologies	Neutral

Summary

Fate Therapeutics beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

How does Invizyne Technologies compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Forte Biosciences had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Forte Biosciences and 0 mentions for Invizyne Technologies. Forte Biosciences' average media sentiment score of 0.47 beat Invizyne Technologies' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Neutral
Invizyne Technologies	Neutral

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 281.55%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Forte Biosciences is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies' return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Invizyne Technologies	N/A	N/A	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Forte Biosciences beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does Invizyne Technologies compare to AC Immune?

Invizyne Technologies (NASDAQ:IZTC) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Invizyne Technologies has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Invizyne Technologies' return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
AC Immune	-1,788.02%	-125.26%	-40.85%

Invizyne Technologies has higher earnings, but lower revenue than AC Immune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
AC Immune	$4.31M	54.54	-$85.03M	-$0.82	N/A

51.4% of AC Immune shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AC Immune has a consensus target price of $7.50, indicating a potential upside of 224.68%. Given AC Immune's stronger consensus rating and higher probable upside, analysts clearly believe AC Immune is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, AC Immune had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for AC Immune and 0 mentions for Invizyne Technologies. AC Immune's average media sentiment score of 1.66 beat Invizyne Technologies' score of 0.00 indicating that AC Immune is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
AC Immune	Very Positive

Summary

AC Immune beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

How does Invizyne Technologies compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Coherus Oncology had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Coherus Oncology and 0 mentions for Invizyne Technologies. Coherus Oncology's average media sentiment score of 1.89 beat Invizyne Technologies' score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Very Positive
Invizyne Technologies	Neutral

72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coherus Oncology currently has a consensus price target of $8.67, indicating a potential upside of 519.05%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Coherus Oncology has a net margin of 397.30% compared to Invizyne Technologies' net margin of 0.00%. Invizyne Technologies' return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Invizyne Technologies	N/A	N/A	N/A

Coherus Oncology has higher revenue and earnings than Invizyne Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

Coherus Oncology beats Invizyne Technologies on 9 of the 11 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IZTC vs. The Competition

Export

Metric	Invizyne Technologies	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.39M	$349.04M	$6.52B	$12.05B
Dividend Yield	N/A	N/A	2.67%	5.66%
P/E Ratio	N/A	N/A	24.00	24.42
Price / Sales	N/A	170.73	533.77	123.88
Price / Cash	N/A	22.44	27.48	37.92
Price / Book	N/A	4.76	10.55	6.82
Net Income	N/A	-$141.03M	$3.57B	$337.56M
7 Day Performance	-23.98%	0.72%	0.59%	1.16%
1 Month Performance	-28.14%	-4.63%	1.55%	3.16%
1 Year Performance	-44.57%	56.79%	25.41%	30.60%

Invizyne Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IZTC Invizyne Technologies	N/A	$7.10 -7.8%	N/A	-44.6%	$44.39M	N/A	N/A	29	Gap Down
NERV Minerva Neurosciences	2.9882 of 5 stars	$4.96 +3.8%	$10.50 +111.7%	+147.1%	$231.08M	N/A	N/A	9
FATE Fate Therapeutics	3.2685 of 5 stars	$1.98 -10.4%	$5.13 +158.8%	+61.6%	$230.79M	$6.65M	N/A	550	Gap Down
FBRX Forte Biosciences	1.8521 of 5 stars	$16.52 -1.0%	$67.00 +305.6%	+45.2%	$229.40M	N/A	N/A	5
ACIU AC Immune	3.0391 of 5 stars	$2.25 -6.3%	$7.50 +233.3%	+18.5%	$228.99M	$4.31M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invizyne Technologies (IZTC) Competitors

IZTC vs. NERV, FATE, FBRX, ACIU, and CHRS

How does Invizyne Technologies compare to Minerva Neurosciences?

Summary

How does Invizyne Technologies compare to Fate Therapeutics?

Summary

How does Invizyne Technologies compare to Forte Biosciences?

Summary

How does Invizyne Technologies compare to AC Immune?

Summary

How does Invizyne Technologies compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invizyne Technologies (IZTC) Competitors

IZTC vs. NERV, FATE, FBRX, ACIU, and CHRS

How does Invizyne Technologies compare to Minerva Neurosciences?

Does the media favor NERV or IZTC?

Which has preferable earnings and valuation, NERV or IZTC?

Do analysts recommend NERV or IZTC?

Is NERV or IZTC more profitable?

Do institutionals & insiders believe in NERV or IZTC?

Summary

How does Invizyne Technologies compare to Fate Therapeutics?

Is FATE or IZTC more profitable?

Do institutionals and insiders believe in FATE or IZTC?

Do analysts rate FATE or IZTC?

Which has higher valuation and earnings, FATE or IZTC?

Does the media prefer FATE or IZTC?

Summary

How does Invizyne Technologies compare to Forte Biosciences?

Which has higher earnings and valuation, FBRX or IZTC?

Does the media refer more to FBRX or IZTC?

Do analysts prefer FBRX or IZTC?

Is FBRX or IZTC more profitable?

Do institutionals & insiders believe in FBRX or IZTC?

Summary

How does Invizyne Technologies compare to AC Immune?

Is IZTC or ACIU more profitable?

Which has stronger valuation & earnings, IZTC or ACIU?

Do institutionals and insiders believe in IZTC or ACIU?

Do analysts rate IZTC or ACIU?

Does the media refer more to IZTC or ACIU?

Summary

How does Invizyne Technologies compare to Coherus Oncology?

Does the media prefer CHRS or IZTC?

Do insiders and institutionals have more ownership in CHRS or IZTC?

Do analysts rate CHRS or IZTC?

Is CHRS or IZTC more profitable?

Which has preferable valuation and earnings, CHRS or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools